Qtr 1 2014
Gross Income... -3.3 m
Total Operating Expense... 31.4 m
Net Operating Income.. -34.4 m
So this company has a negative income, can't get any current drugs past phase 2, NO revenue generating drugs on the market for income.
This company is NOT healthy.
From 3 Reasons to Why Wall Street Hates Idenix Pharmaceuticals, Inc...
At the end of March, Idenix had $205 million in cash and cash equivalents. With a cash burn rate over the trailing-12 months of over $100 million, and only mid-stage (and earlier) candidates in its pipeline, it seems unlikely that management will be able to make the money last through to a potential drug commercialization. In other words, I think you should expect a capital raise and potential share dilution within the next two years and prior to any potential regulatory filing.
The true value of this stock is not $6.27 but much much less.